Cantor Fitzgerald analyst Pablo Zuanic lowered the firm’s price target on Cresco Labs (CRLBF) to $14.25 from $15 and keeps an Overweight rating on the shares after meeting with the company. Management confirmed the acquisition with Columbia Care (CCHWF) is on track to close by end of March, Zuanic tells investors in a research note. However, the analyst sees a challenging 12-18 months for the cannabis sector with no gains on the federal reform front, limited capital access and consumer pressure. For those taking a long-term view, the recent sector selloff generates attractive long-term buying opportunities, writes Zuanic.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CRLBF:
- FDA Contemplates Regulating CBD in Edibles
- Cresco Labs to participate in a conference call with Cantor Fitzgerald
- Cresco Labs downgraded to Market Perform from Outperform at Cowen
- Cannabis Stocks Sink on Exclusion of SAFE Banking Act from Spending Bill
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations